FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

仅供研究使用。 完整免责声明 →

研究/New Clinical Trial Aims to Compare Peptide Therapy with Surgery for Obesity and Diabetes Management
返回研究图书馆

New Clinical Trial Aims to Compare Peptide Therapy with Surgery for Obesity and Diabetes Management

May 25, 2026
Share
新兴研究

基于新兴研究。这些发现很有前景,但需要进一步验证。

关于此分析

本文是基于最近发布的新闻或临床试验公告的人工智能辅助摘要。旨在为肽类研究社区提供快速、易懂的概览。欲获得完整准确性,请参阅下方提供的原始来源。

New Clinical Trial Aims to Compare Peptide Therapy with Surgery for Obesity and Diabetes Management

A groundbreaking new clinical trial has commenced to evaluate the effectiveness of a novel peptide therapy in managing obesity and type 2 diabetes. The study, titled "Side-to-Side Duodeno-Ileostomy Versus Semaglutide," is being conducted by GT Metabolic Solutions, Inc., and seeks to compare the efficacy of semaglutide with a surgical intervention known as side-to-side duodeno-ileostomy.

Background

The management of obesity and type 2 diabetes has seen significant advancements in recent years, particularly through the development of peptide therapies. Peptides are small chains of amino acids that play critical roles in numerous biological processes, including metabolism and appetite regulation. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is one such therapy that has gained widespread recognition for its efficacy in weight loss and glycemic control.

In parallel with pharmacological advancements, surgical interventions have also shown promise in treating these conditions. One such intervention is the side-to-side duodeno-ileostomy, which aims to reroute food through the small intestine to reduce calorie absorption and promote weight loss.

Key Details

The clinical trial, currently recruiting participants via ClinicalTrials.gov (NCT07317115), will compare the long-term effects of semaglutide with those of side-to-side duodeno-ileostomy. The study aims to recruit adults who are living with obesity and type 2 diabetes and assess how each treatment modality affects body weight, glucose control, cardiovascular health, and quality of life.

Participants will be randomly assigned to either receive daily injections of semaglutide or undergo the surgical procedure. Both approaches have shown promise in previous studies, but this trial seeks to provide a more comprehensive comparison by examining outcomes over an extended period.

Key Takeaways

  • Peptide Therapy vs Surgery: The study compares the effectiveness of semaglutide—a peptide-based therapy—with side-to-side duodeno-ileostomy.
  • Patient Selection: Adults with obesity and type 2 diabetes are eligible to participate in the trial, providing valuable insights into these specific patient populations.
  • Long-term Outcomes: By tracking outcomes over an extended period, researchers aim to provide a more complete picture of each treatment's benefits and risks.
  • Regulatory Implications: The results could influence future FDA regulations concerning both pharmaceutical treatments and surgical interventions.

What This Means

For the peptide research community, this trial represents a significant step forward in understanding how non-invasive therapies like semaglutide stack up against more invasive options such as surgery. As researchers continue to explore new applications for peptides in metabolic disorders, studies like this one will be crucial in guiding clinical practice and regulatory decisions.

Moreover, the findings could have broader implications for healthcare providers and patients considering treatment options for obesity and type 2 diabetes. By providing a direct comparison between semaglutide and side-to-side duodeno-ileostomy, the study aims to empower individuals with more informed choices about their health management strategies.

---

Source: ClinicalTrials.gov — Published 2026-05-19

This article is for informational purposes only and does not constitute medical advice.

编辑注释

此分析使用人工智能工具生成,并由Peptide Contacts编辑团队审核。尽管我们力求准确,但人工智能生成的内容可能包含错误或遗漏。鼓励读者查阅 原始来源 以获取完整细节、方法和数据。

Peptide Contacts提供研究摘要仅供信息参考之用。此内容不构成医疗建议。在做出任何健康决策前,请咨询合格的医疗服务提供者。

Comments

Sign in to join the discussion

本文由人工智能生成,可能存在不准确之处。仅供信息参考之用,并不构成医疗建议。请务必通过原始来源核实信息并在做出任何健康决策前咨询合格的医疗服务提供者。